Derycz Scientific announced deal with Cubist Pharmaceuticals for medical literature access
Although the Internet has made published content vastly more accessible and usable, there is still the not-so-small matter of obtaining reprint rights and dealing with the variety of contractural terms that publishers might impose. On the publisher side, access to the market is constrained by having a network that can tap into archived published material.
Enter Derycz Scientific (Santa Monica, CA), which has been working for several years on software and services to streamline the process of obtaining copyrighted material, and the permissions needed to redistribute it, either electronically or on paper. For biopharma companies, Derycz offers a “literature workflow solution” that can provide researchers access to scientific literature; at the same time, its tools help manage the distribution of, say, an important new clinical trial report to the sales and marketing team of the biopharma company.
Recently, Dercyz’ subsidiary, Reprints Desk, Inc. entered into a collaboration with Quosa Inc. (Waltham, MA), another literature-workflow solutions provider, to provide its services to Cubist Pharmaceuticals (Lexington, MA). Peter Dercyz, president, says that the agreement will save Cubist money on reprint rights, as well as speed up delivery of content to the company.
Dercyz Scientific has consolidated rights-access for a number of publishers, most recently the American Institute of Physics, the British Medical Journal Group, the American Academy of Family Physicians, IOS Press and Annual Reviews. Each of these has lists of peer-reviewed journals used by researchers. Dercyz Scientific’s tools include the Mighty Linkout Machine for content access, and Reprints NRx for bulk reprinting of medical/scientific literature.
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.